In clinical trials, tirzepatide led to an average weight loss of up to 22.5% of body weight at the highest dose over 72 weeks, with lower doses producing 15% to 19.6% reduction. These results place tirzepatide among the most effective medications currently available for weight management in people with obesity or overweight.

Key takeaways

  • Average weight loss of 15% to 22.5% depending on dosage and study population.
  • Approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
  • Superior to placebo and to other GLP-1 medications in head-to-head trials.
  • Weight loss is typically sustained over 72 weeks with continued treatment.
  • Common side effects include gastrointestinal symptoms that can be managed with dose titration.

How much weight do people lose with tirzepatide in clinical trials?

In the SURMOUNT-1 trial, participants taking tirzepatide at the 15 mg dose lost an average of 22.5% of their body weight after 72 weeks.

The SURMOUNT-1 study enrolled over 2,500 adults with obesity or overweight who did not have diabetes. After 72 weeks, those taking the weekly injection of 5 mg lost about 15% of their starting weight, while those on 10 mg lost about 19.6% and those on 15 mg lost 22.5%. By comparison, the placebo group lost only about 2.4%. These results were sustained for most participants throughout the study period. Tirzepatide is part of a class of medications called incretin mimetics, and you can read a broader overview of GLP-1 Medications Explained. This class includes other drugs used for diabetes and weight loss. The weight loss achieved with tirzepatide was dose dependent and typically plateaued around 40 to 48 weeks.

What do the SURMOUNT and SURPASS trials tell us about tirzepatide for weight loss?

The SURMOUNT trials tested tirzepatide specifically for weight management, while the SURPASS trials evaluated its effects on blood sugar and weight in people with type 2 diabetes.

In SURMOUNT-2, which included people with type 2 diabetes, average weight loss on the 10 mg and 15 mg doses was 13.4% and 15.7% respectively at 72 weeks. The slightly lower numbers compared to SURMOUNT-1 reflect the metabolic challenge of diabetes. In SURPASS-2, a head-to-head comparison with semaglutide, tirzepatide at the highest dose led to an average 12.9 kg weight loss versus 8.7 kg with semaglutide. Across all trials, weight loss was clearly dose dependent and plateaued after about 40 weeks on average. The studies consistently showed that continued treatment was necessary to maintain the lost weight.

How does tirzepatide compare to other weight loss medications?

In clinical trials, tirzepatide has generally produced greater weight loss than semaglutide and older weight loss drugs, although individual responses vary.

The SURMOUNT-3 trial showed that participants who followed an intensive lifestyle program for 12 weeks and then added tirzepatide lost an average 18.4% of their body weight after 72 weeks, compared to 2.5% with placebo. SURMOUNT-4 evaluated the effects of stopping treatment: those who continued tirzepatide for an additional 52 weeks after the initial 36 weeks maintained their weight loss, while those switched to placebo regained about 14% of their body weight. This underscores the need for ongoing therapy to sustain benefits. In real world settings, results may differ due to adherence, diet, and activity levels. For a deeper look at how these medications work, see the article on GLP-1 Medications Explained.

What factors influence individual tirzepatide weight loss results?

Factors such as starting weight, adherence to medication, diet and exercise habits, and metabolic conditions like diabetes can affect how much weight an individual loses.

While averages are helpful, individual results in trials ranged widely. People with a higher starting body mass index often lost more absolute weight, but the percentage loss was similar across weight categories. Those who also made lifestyle changes tended to lose more weight. Also, people with type 2 diabetes typically lost less weight than those without, likely due to insulin resistance and other metabolic factors. Dose selection also plays a role: many patients start at low doses and escalate every four weeks to minimize side effects. Consistency of injections and staying on the medication for the full duration of treatment are also important for achieving the best results.

Frequently Asked Questions

What is the average weight loss after 72 weeks on tirzepatide?

In the SURMOUNT-1 trial, the average weight loss was 15.0% of body weight for the 5 mg dose, 19.6% for the 10 mg dose, and 22.5% for the 15 mg dose, compared to 2.4% for placebo. These results reflect the average for all participants in the study. Some individuals lost more, and some less. The amount of weight loss was dose dependent, meaning higher doses generally produced more weight loss.

Can tirzepatide help with weight loss in people without diabetes?

Yes, the SURMOUNT-1 trial specifically studied people with obesity or overweight who did not have diabetes. Weight loss results in that population were similar to or slightly greater than those observed in people with type 2 diabetes in other trials. The FDA approval of Zepbound for weight management includes adults with a body mass index of 30 or greater or a BMI of 27 or greater with at least one weight-related condition such as high blood pressure or high cholesterol.

What are the common side effects and how long do they last?

The most common side effects were gastrointestinal: nausea (reported in up to 37% of participants in SURMOUNT-1), diarrhea (31%), vomiting (22%), and constipation (21%). These effects are usually mild to moderate and occur mostly during the dose escalation period. They tend to lessen over time as the body adjusts. Healthcare providers often start with a low dose and increase slowly to reduce side effects. Less common but serious side effects include pancreatitis, gallbladder disease, and kidney injury. Most people who continue treatment find that side effects become manageable within several weeks.

This article is for general information and is not medical advice. See our Medical Disclaimer.